Treatment of Viral Infections During Pregnancy

Clinics in Perinatology

Volumn 46, Issue 2, 2019, Pages 235-256

  Rogan, Sarah C ^a   Beigi, Richard H ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antiviral therapy; Cytomegalovirus; Herpes simplex virus; Human immunodeficiency virus; Maternal to child transmission; Pregnancy; Viral hepatitis; Viral infections

Indexed keywords

ABACAVIR; ACICLOVIR; ATAZANAVIR PLUS RITONAVIR; CIDOFOVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HEPATITIS B VACCINE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; LAMIVUDINE; LEDIPASVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PLACEBO; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOFOSBUVIR; STAVUDINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VALACICLOVIR; ZIDOVUDINE; ANTIVIRUS AGENT;

ANTIRETROVIRAL THERAPY; BREAST FEEDING; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; TERATOGENICITY; VACCINATION; VIRUS INFECTION; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; FEMALE; FETOMATERNAL TRANSFUSION; NEWBORN; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; VERTICAL TRANSMISSION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HERPES SIMPLEX; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 85063457340     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2019.02.009     Document Type: Review

References (149)

1. Looker, K.J., Magaret, A.S., Turner, K.M.E., et al. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One, 10(1), 2015, e114989.
2. Looker, K.J., Magaret, A.S., May, M.T., et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One, 10(10), 2015, e0140765.
3. Mcquillan, G., Kruszon-Moran, D., Flagg, E.W., et al. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. NCHS data brief, no 304. 2018, National Center for Health Statistics, Hyattsville (MD).
4. Brown, Z.A., Selke, S., Zeh, J., et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 337:8 (1997), 509–516.
5. Bernstein, D.I., Bellamy, A.R., Hook, E.W., et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 56:3 (2013), 344–351.
6. Brown, Z.A., Benedetti, J., Ashley, R., et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 324:18 (1991), 1247–1252.
7. Workowski, K.A., Bolan, G.A., Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64:RR-03 (2015), 1–137.
8. ACOG Committee on Practice Bulletins. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. no. 82 June 2007. Management of herpes in pregnancy. Obstet Gynecol 109:6 (2007), 1489–1498.
9. Sheffield, J.S., Hollier, L.M., Hill, J.B., et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 102:6 (2003), 1396–1403.
10. Hollier, L.M., Wendel, G.D., Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev(1), 2008 CD004946.
11. Watts, D.H., Brown, Z.A., Money, D., et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 188:3 (2003), 836–843.
12. Pinninti, S.G., Angara, R., Feja, K.N., et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr 161:1 (2012), 134–138.e1-3.
13. Haddad, J., Langer, B., Astruc, D., et al. Oral acyclovir and recurrent genital herpes during late pregnancy. Obstet Gynecol 82:1 (1993), 102–104.
14. Frenkel, L.M., Brown, Z.A., Bryson, Y.J., et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol 164:2 (1991), 569–576.
15. Kimberlin, D.F., Weller, S., Whitley, R.J., et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol 179:4 (1998), 846–851.
16. Pasternak, B., Hviid, A., Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA, 304(8), 2010, 859.
17. Stone, K.M., Reiff-Eldridge, R., White, A.D., et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 70:4 (2004), 201–207.
18. Staras, S.A.S., Dollard, S.C., Radford, K.W., et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43:9 (2006), 1143–1151.
19. Hyde, T.B., Schmid, D.S., Cannon, M.J., Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 20:5 (2010), 311–326.
20. Dollard, S.C., Grosse, S.D., Ross, D.S., New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17:5 (2007), 355–363.
21. Mussi-Pinhata, M.M., Yamamoto, A.Y., Moura Brito, R.M., et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 49:4 (2009), 522–528.
22. Kenneson, A., Cannon, M.J., Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:4 (2007), 253–276.
23. Wang, C., Zhang, X., Bialek, S., et al. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 52:2 (2011), e11–e13.
24. Gaytant, M.A., Rours, G.I.J.G., Steegers, E.A.P., et al. Congenital cytomegalovirus infection after recurrent infection: case reports and review of the literature. Eur J Pediatr 162:4 (2003), 248–253.
25. Picone, O., Vauloup-Fellous, C., Cordier, A.G., et al. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 33:8 (2013), 751–758.
26. Enders, G., Daiminger, A., Bäder, U., et al. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52:3 (2011), 244–246.
27. Guerra, B., Simonazzi, G., Puccetti, C., et al. Ultrasound prediction of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol, 198(4), 2008, 380.e1-7.
28. Picone, O., Teissier, N., Cordier, A.G., et al. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. Prenat Diagn 34:6 (2014), 518–524.
29. Stagno, S., Whitley, R.J., Herpesvirus infections of pregnancy. N Engl J Med 313:20 (1985), 1270–1274.
30. Fowler, K.B., Stagno, S., Pass, R.F., et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:10 (1992), 663–667.
31. Grosse, S.D., Ross, D.S., Dollard, S.C., Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol 41:2 (2008), 57–62.
32. Nigro, G., Adler, S.P., La Torre, R., et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:13 (2005), 1350–1362.
33. Visentin, S., Manara, R., Milanese, L., et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 55:4 (2012), 497–503.
34. Nigro, G., Adler, S.P., Parruti, G., et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy–a case-control study of the outcome in children. J Infect Dis 205:2 (2012), 215–227.
35. Revello, M.G., Lazzarotto, T., Guerra, B., et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:14 (2014), 1316–1326.
36. Nigro, G., Capretti, I., Manganello, A.-M., et al. Primary maternal cytomegalovirus infections during pregnancy: association of CMV hyperimmune globulin with gestational age at birth and birth weight. J Matern Fetal Neonatal Med 28:2 (2015), 168–171.
37. Chiaie, L.D., Neuberger, P., Vochem, M., et al. No evidence of obstetrical adverse events after hyperimmune globulin application for primary cytomegalovirus infection in pregnancy: experience from a single centre. Arch Gynecol Obstet 297:6 (2018), 1389–1395.
38. Minsart, A.-F., Smiljkovic, M., Renaud, C., et al. Use of cytomegalovirus-specific hyperimmunoglobulins in pregnancy: a retrospective cohort. J Obstet Gynaecol Can 40:11 (2018), 1409–1416.
39. Blázquez-Gamero, D., Galindo Izquierdo, A., Del Rosal, T., et al. Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: a multicenter study in Madrid. J Matern Fetal Neonatal Med 32:4 (2019), 617–625.
40. Jacquemard, F., Yamamoto, M., Costa, J.-M., et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 114:9 (2007), 1113–1121.
41. Leruez-Ville, M., Ghout, I., Bussières, L., et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol 215:4 (2016), 462.e1–462.e10.
42. American College of Obstetricians and Gynecologists, ACOG practice bulletin no. 151: cytomegalovirus, parvovirus B12, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol 125:6 (2015), 1510–1525.
43. Hughes, B.L., Gyamfi-Bannerman, C., Gyamfi-Bannerman, C., Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol 214:6 (2016), B5–B11.
44. Rawlinson, W.D., Boppana, S.B., Fowler, K.B., et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 17:6 (2017), e177–e188.
45. World Health Organization. Global hepatitis report 2017, 2017, World Health Organization, Geneva (Switzerland) Available at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ Accessed August 22, 2018.
46. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection, 2015, World Health Organization, Geneva (Switzerland) Available at: http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/ Accessed August 22, 2018.
47. Dionne-Odom, J., Tita, A.T.N., Silverman, N.S., #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol 214:1 (2016), 6–14.
48. ACOG practice bulletin no. 86: viral hepatitis in pregnancy. Obstet Gynecol 110:4 (2007), 941–956.
49. Mast, E.E., Margolis, H.S., Fiore, A.E., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 54:RR-16 (2005), 1–31.
50. Burk, R.D., Hwang, L.Y., Ho, G.Y., et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 170:6 (1994), 1418–1423.
51. del Canho, R., Grosheide, P.M., Mazel, J.A., et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 15:15 (1997), 1624–1630.
52. Wiseman, E., Fraser, M.A., Holden, S., et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 190:9 (2009), 489–492.
53. Lin, X., Guo, Y., Zhou, A., et al. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population. Pediatr Infect Dis J 33:9 (2014), 897–903.
54. Kubo, A., Shlager, L., Marks, A.R., et al. Prevention of vertical transmission of hepatitis B. Ann Intern Med, 160(12), 2014, 828.
55. Pan, C.Q., Duan, Z., Bhamidimarri, K.R., et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 10:5 (2012), 452–459.
56. Zou, H., Chen, Y., Duan, Z., et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 19:2 (2012), e18–e25.
57. Terrault, N.A., Lok, A.S.F., McMahon, B.J., et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:4 (2018), 1560–1599.
58. Eke, A.C., Eleje, G.U., Eke, U.A., et al. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst Rev(2), 2017 CD008545.
59. Yuan, J., Lin, J., Xu, A., et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat 13:9 (2006), 597–604.
60. Brown, R.S., Verna, E.C., Pereira, M.R., et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the antiretroviral pregnancy registry. J Hepatol 57:5 (2012), 953–959.
61. Han, L., Zhang, H.-W., Xie, J.-X., et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol, 17(38), 2011, 4321.
62. Shi, Z., Yang, Y., Ma, L., et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus. Obstet Gynecol 116:1 (2010), 147–159.
63. Greenup, A.-J., Tan, P.K., Nguyen, V., et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 61:3 (2014), 502–507.
64. Chen, H.-L., Lee, C.-N., Chang, C.-H., et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 62:2 (2015), 375–386.
65. Pan, C.Q., Duan, Z., Dai, E., et al. Tenofovir to Prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 374:24 (2016), 2324–2334.
66. Jourdain, G., Ngo-Giang-Huong, N., Harrison, L., et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med 378:10 (2018), 911–923.
67. Terrault, N.A., Feld, J.J., Lok, A.S.F., Tenofovir to prevent perinatal transmission of hepatitis B. N Engl J Med 378:24 (2018), 2348–2350.
68. Dusheiko, G., A shift in thinking to reduce mother-to-infant transmission of hepatitis B. N Engl J Med 378:10 (2018), 952–953.
69. Lee, D., Shin, H.-Y., Park, S.M., Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea. Cost Eff Resour Alloc, 16(1), 2018, 6.
70. Nayeri, U.A., Werner, E.F., Han, C.S., et al. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. Am J Obstet Gynecol, 207(3), 2012, 231.e1-7.
71. Terrault, N.A., Bzowej, N.H., Chang, K.-M., et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63:1 (2016), 261–283.
72. Schillie, S., Vellozzi, C., Reingold, A., et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 67:1 (2018), 1–31.
73. ACOG practice advisory: hepatitis B prevention, 2018 Available at: http://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Hepatitis-B-Prevention Accessed November 14, 2018.
74. Conte, D., Fraquelli, M., Prati, D., et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 31:3 (2000), 751–755.
75. Pergam, S.A., Wang, C.C., Gardella, C.M., et al. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol, 199(1), 2008, 38.e1-9.
76. Reddick, K.L.B., Jhaveri, R., Gandhi, M., et al. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat 18:7 (2011), e394–e398.
77. Huang, Q.-T., Hang, L.-L., Zhong, M., et al. Maternal HCV infection is associated with intrauterine fetal growth disturbance: a meta-analysis of observational studies. Medicine (Baltimore), 95(35), 2016, e4777.
78. Connell, L.E., Salihu, H.M., Salemi, J.L., et al. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int 31:8 (2011), 1163–1170.
79. Wijarnpreecha, K., Thongprayoon, C., Sanguankeo, A., et al. Hepatitis C infection and intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 41:1 (2017), 39–45.
80. Benova, L., Mohamoud, Y.A., Calvert, C., et al. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 59:6 (2014), 765–773.
81. Resti, M., Azzari, C., Mannelli, F., et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany study group on hepatitis C virus infection. BMJ 317:7156 (1998), 437–441.
82. Zanetti, A.R., Paccagnini, S., Principi, N., et al. Mother-to-infant transmission of hepatitis C virus. Lancet 345:8945 (1995), 289–291.
83. Gibb, D.M., Goodall, R.L., Dunn, D.T., et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 356:9233 (2000), 904–907.
84. Yeung, L., King, S.M., Roberts, E.A., Mother-to-infant transmission of hepatitis C virus. Hepatology 34:2 (2001), 223–229.
85. Hughes, B.L., Page, C.M., Kuller, J.A., Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol 217:5 (2017), B2–B12.
86. AASLD-IDSA, Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org Accessed August 29, 2018.
87. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection, 2018, World Health Organization, Geneva (Switzerland) Available at: http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/ Accessed August 22, 2018.
88. Jazwinski, A.B., Muir, A.J., Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) 7:3 (2011), 154–162.
89. Barritt, A.S., Jhaveri, R., Treatment of hepatitis C during pregnancy-weighing the risks and benefits in contrast to HIV. Curr HIV/AIDS Rep 15:2 (2018), 155–161.
90. Centers for Disease Control and Prevention. HIV surveillance report, 2017, vol. 29, 2018 Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html Accessed November 21, 2018.
91. Whitmore, S.K., Zhang, X., Taylor, A.W., et al. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr 57:3 (2011), 218–222.
92. Connor, E.M., Sperling, R.S., Gelber, R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331:18 (1994), 1173–1180.
93. Cooper, E.R., Charurat, M., Mofenson, L., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29:5 (2002), 484–494.
94. Forbes, J.C., Alimenti, A.M., Singer, J., et al. A national review of vertical HIV transmission. AIDS 26:6 (2012), 757–763.
95. Mandelbrot, L., Tubiana, R., Le Chenadec, J., et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis 61:11 (2015), 1715–1725.
96. Panel on treatment of pregnant women with HIV infection and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf Accessed November 21, 2018.
97. Mofenson, L.M., Lambert, J.S., Stiehm, E.R., et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 341:6 (1999), 385–393.
98. Townsend, C.L., Byrne, L., Cortina-Borja, M., et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 28:7 (2014), 1049–1057.
99. Hoffman, R.M., Black, V., Technau, K., et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 54:1 (2010), 35–41.
100. Siegfried, N., van der Merwe, L., Brocklehurst, P., et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev(7), 2011 CD003510.
101. Fowler, M.G., Qin, M., Fiscus, S.A., et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 375:18 (2016), 1726–1737.
102. Briand, N., Warszawski, J., Mandelbrot, L., et al. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?. Clin Infect Dis 57:6 (2013), 903–914.
103. Tubiana, R., Le Chenadec, J., Rouzioux, C., et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 Copies/mL at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 50:4 (2010), 585–596.
104. Graham, S.M., Holte, S.E., Peshu, N.M., et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 21:4 (2007), 501–507.
105. Fiore, J.R., Suligoi, B., Saracino, A., et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 17:15 (2003), 2169–2176.
106. King, C.C., Ellington, S.R., Davis, N.L., et al. Prevalence, magnitude, and correlates of HIV-1 genital shedding in women on antiretroviral therapy. J Infect Dis 216:12 (2017), 1534–1540.
107. Cu-Uvin, S., DeLong, A.K., Venkatesh, K.K., et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 24:16 (2010), 2489–2497.
108. Launay, O., Tod, M., Tschöpe, I., et al. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther 16:6 (2011), 843–852.
109. John, G.C., Nduati, R.W., Mbori-Ngacha, D.A., et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 183:2 (2001), 206–212.
110. McCormack, S.A., Best, B.M., Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet 53:11 (2014), 989–1004.
111. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2016, World Health Organization, Geneva (Switzerland) Availabe at: http://www.who.int/hiv/pub/arv/arv-2016/en/ Accessed November 21, 2018.
112. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry interim report for 1 January 1989 through 31 January 2018. 2017, Registry Coordinating Center, Wilmington (NC) Available at: www.APRegistry.com Accessed September 24, 2018.
113. Zash, R., Makhema, J., Shapiro, R.L., Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 379:10 (2018), 979–981.
114. Knapp, K.M., Brogly, S.B., Muenz, D.G., et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 31:2 (2012), 164–170.
115. Brogly, S.B., Abzug, M.J., Watts, D.H., et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 29:8 (2010), 721–727.
116. Williams, P.L., Crain, M.J., Yildirim, C., et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 169:1 (2015), 48–55.
117. Sibiude, J., Mandelbrot, L., Blanche, S., et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med, 11(4), 2014, e1001635.
118. Sibiude, J., Le Chenadec, J., Bonnet, D., et al. In Utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial. Clin Infect Dis 61:2 (2015), 270–280.
119. Townsend, C., Schulte, J., Thorne, C., et al. Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG 117:11 (2010), 1399–1410.
120. Kourtis, A.P., Schmid, C.H., Jamieson, D.J., et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 21:5 (2007), 607–615.
121. Wedi, C.O., Kirtley, S., Hopewell, S., et al. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. Lancet HIV 3:1 (2016), e33–e48.
122. Chagomerana, M.B., Miller, W.C., Pence, B.W., et al. PMTCT option B+ does not increase preterm birth risk and may prevent extreme prematurity: a retrospective cohort study in Malawi. J Acquir Immune Defic Syndr 74:4 (2017), 367–374.
123. Schulte, J., Dominguez, K., Sukalac, T., et al. Pediatric spectrum of HIV disease consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics 119:4 (2007), e900–e906.
124. Cotter, A.M., Garcia, A.G., Duthely, M.L., et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?. J Infect Dis 193:9 (2006), 1195–1201.
125. Powis, K.M., Kitch, D., Ogwu, A., et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 204:4 (2011), 506–514.
126. Ekouevi, D.K., Coffie, P.A., Becquet, R., et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS 22:14 (2008), 1815–1820.
127. Njom Nlend, A.E., Nga Motazé, A., Moyo Tetang, S., et al. Preterm birth and low birth weight after in utero exposure to antiretrovirals initiated during pregnancy in yaoundé, Cameroon. PLoS One, 11(3), 2016, e0150565.
128. Briand, N., Mandelbrot, L., Le Chenadec, J., et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 23:10 (2009), 1235–1243.
129. Tuomala, R.E., Shapiro, D.E., Mofenson, L.M., et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 346:24 (2002), 1863–1870.
130. Szyld, E.G., Warley, E.M., Freimanis, L., et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 20:18 (2006), 2345–2353.
131. Read, D.J.S., Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 189:12 (2004), 2154–2166.
132. Arikawa, S., Rollins, N., Jourdain, G., et al. Contribution of maternal antiretroviral therapy and breastfeeding to 24-month survival in human immunodeficiency virus-exposed uninfected children: an individual pooled analysis of African and Asian studies. Clin Infect Dis 66:11 (2018), 1668–1677.
133. Rousseau, C.M., Nduati, R.W., Richardson, B.A., et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 187:5 (2003), 741–747.
134. Flynn, P.M., Taha, T.E., Cababasay, M., et al. Prevention of HIV-1 transmission through breastfeeding. J Acquir Immune Defic Syndr 77:4 (2018), 383–392.
135. Chasela, C.S., Hudgens, M.G., Jamieson, D.J., et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 362:24 (2010), 2271–2281.
136. White, A.B., Mirjahangir, J.F., Horvath, H., et al. Antiretroviral interventions for preventing breast milk transmission of HIV. Cochrane Database Syst Rev(10), 2014 CD011323.
137. Marazzi, M.C., Nielsen-Saines, K., Buonomo, E., et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J 28:6 (2009), 483–487.
138. Dinh, T.-H., Mushavi, A., Shiraishi, R.W., et al. Impact of timing of antiretroviral treatment and birth weight on mother-to-child human immunodeficiency virus transmission: findings from an 18-month prospective cohort of a nationally representative sample of mother-infant pairs during the transition from option A to option B+ in Zimbabwe. Clin Infect Dis 66:4 (2018), 576–585.
139. Kesho Bora Study Group de Vincenzi, I., Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11:3 (2011), 171–180.
140. Waitt, C.J., Garner, P., Bonnett, L.J., et al. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother 70:7 (2015), 1928–1941.
141. Waitt, C., Olagunju, A., Nakalema, S., et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. J Antimicrob Chemother 73:4 (2018), 1013–1019.
142. Corbett, A.H., Kayira, D., White, N.R., et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN Study. Antivir Ther 19:6 (2014), 587–595.
143. Mugwanya, K.K., Hendrix, C.W., Mugo, N.R., et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med, 13(9), 2016, e1002132.
144. Palombi, L., Pirillo, M.F., Marchei, E., et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the option B-plus approach in Malawi. J Antimicrob Chemother 71:4 (2016), 1027–1030.
145. Zeh, C., Weidle, P.J., Nafisa, L., et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med, 8(3), 2011, e1000430.
146. Fogel, J., Li, Q., Taha, T.E., et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 52:8 (2011), 1069–1076.
147. Shapiro, R.L., Hughes, M.D., Ogwu, A., et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362:24 (2010), 2282–2294.
148. ACOG committee opinion no. 741. Maternal immunization. Obstet Gynecol 131:6 (2018), e214–e217.
149. Kroger, A.T., Duchin, J., Vázquez, M., General best practice guidelines for immunization. best practices guidance of the advisory committee on immunization practices (ACIP). Available at: http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html Accessed December 18, 2018.